Description: List of key initiatives for the Society of Actuaries and how they were developed.

Description: Editorial on financial crisis.

Description: Column listing candidates in the SOA 2009 board elections.

Description: The world is facing a complex and rapidly evolving landscape of risks that threaten global stability and prosperity. From escalating geopolitical tensions and trade conflicts to the looming specter of economic downturns and disruptive technological change, a perfect storm of emerging risks is challenging governments, businesses, and individuals alike. As the interconnected nature of our globalized world amplifies the potential impact of these risks, it has become increasingly crucial for decision-makers to understand and proactively address the multifaceted challenges that lie ahead. This article will explore some of the key emerging risks and their implications, offering insights to help navigate these turbulent times.

Description: This article presents the Bachelor of Actuarial Science at the University of Bahrain. From the its development to its perspective, we describe the strengths and how academic staff members are taking care of different aspects of the program.

Description: As the new VM-22 framework reshapes reserving for non-variable annuities, actuaries face both opportunities and challenges. Our latest insight and highlights what you need to know about assumption setting, model validation and asset optimization ahead of 2026.

Description: Update on IFRS 17 including news, how IFRS 17 is impacting companies financials, comparisons to LDTI, and KPIs.

Description: Latest development in IFRS 17 including a first look at companies disclosures and financial impacts, as well as a discussion of some of the run time issues that companies face.

Description: Provides an update, as of September 2022, on Financial Reporting Section sponsored research projects in process and those recently completed.

Description: What are Biosimilar drugs? Are they the same as generic drugs? What potential impact might Biosimilars have in the United States prescription drug landscape and it’s economics? This article explores those questions as well as exclusivity and interchangeability.